H.C. Wainwright initiated coverage on Damora Therapeutics with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for DMRA
Across the 10 sessions after earlier DMRA headlines, the stock closed higher 3 times and lower 7 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DMRA | SPY |
|---|---|---|---|
| Jun 8, 2026 | TD Cowen initiated coverage on Damora Therapeutics | -0.5% | +0.2% |
| Jun 1, 2026 | Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -0.1% | +0.3% |
| May 28, 2026 | Wedbush initiated coverage on Damora Therapeutics with a new price target | -1.5% | +0.6% |
| May 13, 2026 | Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | +4.6% | +0.6% |
| May 1, 2026 | Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.2% | +0.3% |
| Apr 24, 2026 | RBC Capital Mkts initiated coverage on Damora Therapeutics with a new price target | -2.6% | +0.8% |
Quantisnow market dataNASDAQ
DMRA
Damora Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for DMRA
Full DMRA profile on Quantisnow Follow DMRA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time